Myasthenia gravis (MG) is a rare condition that affects approximately 36,000 to 60,000 individuals in the United States. Even though there are a variety of treatment options, it can be difficult to predict symptom flare-ups. Creative approaches are necessary to provide the best outcomes for patients.
Continue reading